Phosphate Handling
On this page
Direct answer
Bones bank about 85% of the body's phosphate, soft tissues hold most of the rest as the phosphate of ATP, phospholipids and nucleotides, and under 1% circulates in extracellular fluid at a concentration of 2.5-4.5 mg/dL — a fraction defended mainly by the proximal tubule, which reabsorbs 80-90% of the filtered load through sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc). Two phosphaturic hormones control that number: parathyroid hormone, which internalises the cotransporters within minutes, and fibroblast growth factor 23 from osteocytes, which requires its co-receptor Klotho and additionally suppresses renal 1-alpha-hydroxylase while lowering parathyroid hormone itself. Because phosphate rides cellular metabolism, clinical trouble comes from two directions: acute hypophosphataemia from the intracellular shift of refeeding (the crash of ATP and 2,3-DPG in malnourished and alcoholic patients), and chronic hyperphosphataemia in chronic kidney disease, where retained phosphate drives secondary hyperparathyroidism, vascular calcification and renal bone disease.
What you must remember
- Distribution and normal range: 85% bone, 14% intracellular organic phosphates, under 1% in extracellular fluid at 2.5-4.5 mg/dL; roughly a tenth is protein-bound, the remainder ultrafiltrable.
- Reabsorptive machinery: proximal tubular NaPi-IIa/IIc cotransporters recover 80-90% of filtered phosphate; the transporters are the regulated step, not filtration.
- Parathyroid hormone action: rapid (minutes) internalisation and degradation of NaPi transporters — phosphaturic, hypercalcaemic in net effect, and rises in phosphate retention.
- Fibroblast growth factor 23: osteocyte-derived hormone acting through FGFR1 plus Klotho; phosphaturic, suppresses 1,25-dihydroxy vitamin D synthesis (unlike PTH which raises it) and directly lowers PTH — the three differences examiners ask for.
- Hypophosphataemia settings: refeeding syndrome (insulin-driven cellular uptake after starvation or alcohol misuse), respiratory alkalosis (intracellular shift), diabetic ketoacidosis recovery, osmotic diuresis and antacid binding — weakness, rhabdomyolysis, respiratory muscle failure and haemolysis at levels under about 1 mg/dL.
- Hyperphosphataemia settings: chronic kidney disease above stage 3-4, tumour lysis, rhabdomyolysis and hypoparathyroidism; the chronic kidney disease-mineral bone disorder sequence of retained phosphate, falling calcitriol, rising PTH and vascular calcification.
- Inherited anchors: X-linked hypophosphataemic rickets (PHEX mutation, FGF23 excess, low phosphate with calcium normal) and tumour-induced osteomalacia — the physiology of FGF23 excess made clinical.
A refeeding scenario, walked stepwise
A severely malnourished adolescent admitted with anorexia nervosa is started on feeds and on day three develops diplopia, respiratory weakness and phosphate at 0.9 mg/dL with potassium 2.9 mEq/L and magnesium 1.3 mg/dL. Sequence the physiology: insulin rises with carbohydrate, driving glucose, phosphate, potassium and magnesium into cells for ATP synthesis and glycogen storage (each gram of glycogen sequesters phosphate); thiamine-dependent pathways accelerate; the suddenly anabolic liver and muscle drain a circulation already running on empty. The prevention is the treatment: start feeds at 5-10 kcal per kg per day in the highest-risk patients, give thiamine before the first feed, and monitor phosphate, potassium, magnesium daily for the first week — the standard refeeding precaution that NICE guidance formalised and Indian hospital protocols increasingly mirror. Now the mirror image in a dialysis-stage patient: phosphate 6.8 mg/dL with raised PTH and pruritus; dietary phosphate restriction, calcium or non-calcium binders with meals, and adjusted dialysis all target the same cotransporter logic from the retention end.
Where students slip
The PTH-FGF23 comparison is where marks are lost: both are phosphaturic, but PTH stimulates 1-alpha-hydroxylase while FGF23 suppresses it, and FGF23 lowers PTH while phosphate retention raises it — draw the loop in words before answering. Second, students call vitamin D simply a "phosphate-raising vitamin": correct in net terms (intestinal absorption of both ions), but in chronic kidney disease the failing 1-alpha-hydroxylase and rising FGF23 both collapse calcitriol, so the phosphate rises before the calcium falls. Third, refeeding hypophosphataemia is misattributed to "dilution"; it is an intracellular uptake event, which is precisely why it can kill through ATP failure rather than through concentration alone. Finally, do not forget respiratory alkalosis as a cause — transcellular shift, not loss — a favourite one-line answer in university papers.
Frequently asked questions
How much filtered phosphate does the proximal tubule reabsorb?
About 80-90%, via sodium-dependent NaPi-IIa and NaPi-IIc cotransporters, whose internalisation by PTH and FGF23 produces phosphaturia.
How does FGF23 differ from PTH in phosphate-vitamin D control?
Both are phosphaturic, but FGF23 (acting with Klotho) suppresses 1-alpha-hydroxylase and lowers PTH, whereas PTH stimulates the enzyme — so FGF23 lowers 1,25-dihydroxy vitamin D while PTH raises it.
Why does refeeding starved patients cause hypophosphataemia?
Insulin drives phosphate into cells for ATP and glycogen synthesis, depleting an already marginal extracellular pool within 24-72 hours of feeding.
What is the chronic kidney disease-mineral bone disorder sequence?
Retained phosphate and falling calcitriol raise PTH chronically, producing bone resorption, brown tumours and extra-skeletal calcification alongside rising FGF23.
Which inherited disorder causes FGF23-mediated phosphate wasting?
X-linked hypophosphataemic rickets from PHEX mutations — rickets with low serum phosphate, normal calcium and urinary phosphate wasting.